The BioPharmX management team consists of seasoned global executives, scientists and business professionals combining large company discipline and early stage company creativity with deep biotech expertise focused on drug delivery and execution of complex development programs. The team has the proven ability to streamline new technologies into viable, marketable and successful products.
David S. Tierney, M.D., Chief Executive Officer and President
An experienced entrepreneurial pharmaceutical and med-tech C-level executive, Dr. Tierney has an extensive track record of delivering success. He has overseen the growth and successful exit of a number of specialty pharmaceutical and medical device companies. Most recently, Dr. Tierney served as president and chief executive officer of Icon Bioscience, leading his team to FDA approval of its New Drug Application (NDA) for DEXYCU™ in 2018. Dr. Tierney was president and chief operating officer of Oceana Therapeutics, a specialty therapeutic company he co-founded in 2008 and was later acquired by Salix Pharmaceuticals. In his role as president and chief executive officer of Valera Pharmaceuticals, Tierney raised over $65 million in funding and completed a successful IPO and oversaw NDA approvals of VANTAS™ and SUPPRELIN LA™. In addition to Dr. Tierney’s leadership roles, he has extensive experience in raising capital and has held a position with investment firm, Signet Health Partners. He is the recipient of two Ernst & Young Entrepreneur of the Year® awards. Dr. Tierney also serves on the board of directors of Catalyst Pharmaceuticals, Kempharm, Bimeda, and Palvella Therapeutics. Dr. Tierney received his medical degree from The Royal College of Surgeons in Dublin, Ireland.
Kin F. Chan, Ph.D., Executive Vice President of Research and Technology
Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BioPharmX, Chan was Vice President of Engineering at Dermira, where he helped develop photodynamic therapies, and directed advanced research at Solta Medical, where he helped create fractional photothermolysis technology. He is a named inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.
Joyce Goto, Chief Accounting Officer
Ms. Goto brings over 20 years of financial management and accounting experience to BioPharmX. Prior to joining BioPharmX, she was corporate controller at MoSys, a publicly held company and provider of semiconductor solutions for cloud networking, security, test and video systems. Prior to this role, she was divisional controller at Pinnacle Systems, now a division of Avid Technology, a publicly held company. Ms. Goto also held various positions at Deloitte and Touche, LLP, a public accounting firm. Ms. Goto holds a Bachelor of Science in Accounting from Cal Poly, San Luis Obispo and is a certified public accountant.
AnnaMarie Daniels, Executive Vice President of Regulatory and Clinical Affairs
Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation and served as an independent consultant for a number of pharmaceutical and medical device companies.
G. Scott Herron, M.D., Ph.D., Medical Director
Dr. Herron is a physician scientist with nearly three decades of dermatology experience and maintains an active clinical practice in Palo Alto, California. As faculty at Stanford University School of Medicine he conducted biomedical research, consulted with the biopharmaceutical industry, authored or co-authored more than 30 peer-reviewed papers, and secured several patents in the biomedical field. In addition he held the position of medical director for Reliant Technologies. Dr. Herron has been honored for his work in the field and is repeatedly recognized as a thought-leading physician. He graduated from Lewis and Clark College with degrees in chemistry and biology, completed his doctoral work at Oregon State University in biochemistry and biophysics and obtained his medical doctor degree from University of Southern California Medical School.